Complete recovery from COVID-19 of a kidney-pancreas transplant recipient: potential benefit from everolimus?
BMJ Case Rep
; 14(1)2021 Jan 11.
Article
in English
| MEDLINE | ID: covidwho-1020889
ABSTRACT
We present a kidney-pancreas transplant recipient who achieved complete recovery from COVID-19. A 45-year-old patient with T3 paraplegia underwent kidney-pancreas transplantation 18 years ago, followed by a subsequent kidney transplant 9 years ago, and presented with fever, hypoxia and hypotension after exposure to two confirmed cases of COVID-19. History of solid organ transplant, pre-existing renal impairment, asthma and an elevated D-dimer were identified as established risk factors for severe COVID-19. Supportive management was provided, baseline immunosuppression with everolimus was continued, and oral prednisolone was increased. A complete recovery was observed. Given the favourable outcome despite risk factors for severe COVID-19, we identify and review the potential mitigating roles of immunosuppression and mammalian target of rapamycin (mTOR) inhibitors in this disease. Further investigation is required to establish whether mTOR inhibitors could be used as therapeutic agents to treat COVID-19, or as alternative immunosuppression implemented early in the COVID-19 disease course.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Paraplegia
/
Kidney Transplantation
/
Pancreas Transplantation
/
COVID-19
/
Glucocorticoids
/
Graft Rejection
/
Immunosuppressive Agents
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2020-238413
Similar
MEDLINE
...
LILACS
LIS